The SGLT2 inhibitor may provide a new hope for chronic kidney disease.
The US Food and Drug Administration (FDA) has given the green light to Jardiance (empagliflozin), a medication designed to mitigate the risk of chronic kidney disease (CKD) progression, end-stage kidney disease, cardiovascular death, and hospitalization in adults. This approval marks a significant step forward in the treatment of CKD, offering a new option for healthcare professionals and hope for patients.
- The FDA approval is based on data from the phase 3 EMPA-KIDNEY trial, which included 6609 adults with CKD.
- The trial showed that treatment with empagliflozin reduced the risk of kidney disease progression or CV death by 28% compared with placebo.
- Empagliflozin was also associated with a 14% reduction in the risk of first and recurrent hospitalization compared with placebo.
- Approximately 44% of the study population had type 2 diabetes.
- Jardiance is not recommended for the treatment of CKD in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy.
According to the National Kidney Foundation, approximately 37 million people in the United States have chronic kidney disease, and millions more are at risk.
More on Kidney Disease